An Open Label Trial of TMS Therapy for Bipolar Depression

Overview

About this study

Transcranial Magnetic Stimulation (TMS) is an increasingly accepted neurostimulation- based treatment for major depressive disorder. While there is a growing anecdotal database supporting its use in bipolar depression the investigators propose to collect open label efficacy and safety data in a small population of patients with clinically verified bipolar disorder.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria- Phase II:

  1. Must be at least 18 years old.
  2. Must meet DSM-5 criteria for bipolar (either I or II) depression by clinical interview and M.I.N.I. The duration of the current depressive episode must be at least 4 weeks and no longer than 3 years in length.
  3. Should have a MADRS score of at least 20 at screening, an YMRS score of less than 12 and a CGI score of at least 4.
  4. Must have signed the informed consent document and have a level of understanding sufficient to provide informed consent and to communicate with the investigator and site personnel.
  5. Must be on a mood stabilizer acceptable to the study physician which is consistent with their diagnosis. The mood stabilizer must be at a stable dose for at least four days before starting TMS treatment.
  6. If female of childbearing potential, patients must
    1. have a negative urine pregnancy test at screening, and
    2. not be nursing or planning a pregnancy, and
    3. be on a medically acceptable method of birth control acceptable to the principal investigator.

Choices of contraception that meet the study requirements are:

  • Intrauterine device
  • Hormonal contraception (estrogen-containing birth control pills, Vaginal ring, patch, injections or implants)
  • Latex condom with spermicide
  • Diaphragm with spermicide
  • Cervical cap with spermicide

Females of childbearing potential who are abstinent can enroll in the study.

Exclusion Criteria- Phase II:

  1. May not be directly affiliated with Sheppard Pratt Clinical Research Programs or be immediate family of Research Programs personnel.
  2. Must not have another primary Axis I diagnosis.
  3. The subject must not have stopped an antidepressant less than two weeks before starting TMS treatment or unable to discontinue antidepressant therapy.
  4. Should have no previous history of psychosis or substance dependence or abuse within the six months prior to Screening
  5. Presence of an Axis II disorder felt by the investigator to potentially interfere with study compliance would exclude a potential participant.
  6. Should not have prior intolerance of TMS or significant lack of response to adequate trials of TMS.
  7. Should not have a lifetime history of lack of response to ECT or VNS.
  8. Should not have any medical condition likely to interfere with safe study participation.
  9. Women of child-bearing potential who are not using a medically accepted means of contraception when engaging in sexual intercourse are excluded, as well as women who are pregnant or breast-feeding.
  10. Positive urine screen for any substance of abuse will exclude a patient, with the exception of benzodiazepines. A satisfactory explanation in the opinion of the investigator along with a negative repeat screen prior to Visit 2 is possibly acceptable.
  11. Current suicide risk, as evidenced:
    1. It is the judgment of the investigator that the patient may be at risk for suicide
    2. The patient has rated a "yes" to question 4 or question 5 on the Screening C-SSRS
    3. The patient has attempted suicide within the past 12 months prior to Screening.
  12. History of head injury, epilepsy or seizure disorder, non-removable metallic implants or objects in or around the head.

Inclusion Criteria- Phase III Patients who meet MADRS criteria for response or remission will enter Phase III, the six month follow-up phase of the study.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Simon Kung, M.D.

Contact us for the latest status

Contact information:

Cynthia Stoppel CCRP

(507) 284-5914

Stoppel.Cynthia@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available